Tempest Therapeutics Stock Buy Hold or Sell Recommendation
| TPST Stock | USD 1.26 0.04 3.08% |
Given the investment horizon of 90 days and your way above-average risk tolerance, our recommendation regarding Tempest Therapeutics is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Tempest Therapeutics given historical horizon and risk tolerance towards Tempest Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Tempest Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Tempest Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Tempest Stock please use our How to Invest in Tempest Therapeutics guide. Note, we conduct extensive research on individual companies such as Tempest and provide practical buy, sell, or hold advice based on investors' constraints. Tempest Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Tempest |
Execute Tempest Therapeutics Buy or Sell Advice
The Tempest recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Tempest Therapeutics. Macroaxis does not own or have any residual interests in Tempest Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Tempest Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Tempest Therapeutics Trading Alerts and Improvement Suggestions
| Tempest Therapeutics generated a negative expected return over the last 90 days | |
| Tempest Therapeutics has high historical volatility and very poor performance | |
| Tempest Therapeutics may become a speculative penny stock | |
| Tempest Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (29.49 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tempest Therapeutics currently holds about 51.62 M in cash with (27.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from finance.yahoo.com: Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs |
Tempest Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Tempest analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Tempest analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Tempest Therapeutics Returns Distribution Density
The distribution of Tempest Therapeutics' historical returns is an attempt to chart the uncertainty of Tempest Therapeutics' future price movements. The chart of the probability distribution of Tempest Therapeutics daily returns describes the distribution of returns around its average expected value. We use Tempest Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Tempest Therapeutics returns is essential to provide solid investment advice for Tempest Therapeutics.
| Mean Return | -0.5 | Value At Risk | -8.53 | Potential Upside | 10.07 | Standard Deviation | 6.78 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Tempest Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Tempest Stock Institutional Investors
The Tempest Therapeutics' institutional investors refer to entities that pool money to purchase Tempest Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Bank Of America Corp | 2024-06-30 | 43.3 K | State Street Corp | 2024-06-30 | 41.5 K | Tocqueville Asset Management L.p. | 2024-06-30 | 40.8 K | Advisor Group Holdings, Inc. | 2024-06-30 | 25.4 K | Dimensional Fund Advisors, Inc. | 2024-06-30 | 25.1 K | Boothbay Fund Management, Llc | 2024-06-30 | 24.6 K | Northern Trust Corp | 2024-06-30 | 20.4 K | Maytech Global Investments, Llc | 2024-06-30 | 10 K | Parallel Advisors, Llc | 2024-06-30 | 236 | Blackrock Inc | 2024-06-30 | 550.2 K | Fmr Inc | 2024-06-30 | 431.9 K |
Tempest Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (9.8M) | 15.6M | 33.0M | (20.2M) | 8M | 8.6M | |
| Free Cash Flow | (41.6M) | (19.1M) | (26.1M) | (31.6M) | (27.5M) | (28.9M) | |
| Depreciation | 1.1M | 339K | 374K | 638K | 381K | 584.3K | |
| Other Non Cash Items | 6.9M | 470K | 1.5M | 1.6M | 5.5M | 5.7M | |
| Capital Expenditures | 397K | 50K | 135K | 562K | 170K | 161.5K | |
| Net Income | (44.6M) | (19.2M) | (28.3M) | (35.7M) | (29.5M) | (31.0M) | |
| End Period Cash Flow | 63.5M | 18.8M | 51.8M | 31.6M | 39.2M | 38.6M |
Tempest Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Tempest Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Tempest Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Tempest stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.88 | |
β | Beta against Dow Jones | 3.42 | |
σ | Overall volatility | 6.94 | |
Ir | Information ratio | -0.09 |
Tempest Therapeutics Volatility Alert
Tempest Therapeutics is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Tempest Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Tempest Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Tempest Therapeutics Fundamentals Vs Peers
Comparing Tempest Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Tempest Therapeutics' direct or indirect competition across all of the common fundamentals between Tempest Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Tempest Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Tempest Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Tempest Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Tempest Therapeutics to competition |
| Fundamentals | Tempest Therapeutics | Peer Average |
| Return On Equity | -2.89 | -0.31 |
| Return On Asset | -0.54 | -0.14 |
| Current Valuation | 21.9 M | 16.62 B |
| Shares Outstanding | 25.21 M | 571.82 M |
| Shares Owned By Insiders | 0.24 % | 10.09 % |
| Shares Owned By Institutions | 22.43 % | 39.21 % |
| Number Of Shares Shorted | 2.05 M | 4.71 M |
| Price To Earning | 0.23 X | 28.72 X |
| Price To Book | 2.01 X | 9.51 X |
| EBITDA | (28.78 M) | 3.9 B |
| Net Income | (29.49 M) | 570.98 M |
| Cash And Equivalents | 51.62 M | 2.7 B |
| Cash Per Share | 4.95 X | 5.01 X |
| Total Debt | 20.66 M | 5.32 B |
| Debt To Equity | 0.49 % | 48.70 % |
| Current Ratio | 3.05 X | 2.16 X |
| Book Value Per Share | 0.69 X | 1.93 K |
| Cash Flow From Operations | (27.36 M) | 971.22 M |
| Short Ratio | 0.37 X | 4.00 X |
| Earnings Per Share | (1.60) X | 3.12 X |
| Target Price | 18.6 | |
| Number Of Employees | 17 | 18.84 K |
| Beta | -2.88 | -0.15 |
| Market Capitalization | 32.77 M | 19.03 B |
| Total Asset | 51.6 M | 29.47 B |
| Retained Earnings | (165.26 M) | 9.33 B |
| Working Capital | 30.95 M | 1.48 B |
| Net Asset | 51.6 M |
Note: Acquisition by Dubensky Thomas W. of 102700 shares of Tempest Therapeutics subject to Rule 16b-3 [view details]
Tempest Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Tempest . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 15414.32 | |||
| Daily Balance Of Power | (0.57) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 1.3 | |||
| Day Typical Price | 1.28 | |||
| Price Action Indicator | (0.06) | |||
| Period Momentum Indicator | (0.04) |
About Tempest Therapeutics Buy or Sell Advice
When is the right time to buy or sell Tempest Therapeutics? Buying financial instruments such as Tempest Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Tempest Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run SPAC Thematic Idea Now
SPAC
Entities that are involved in raising capital, merging with and acquiring companies, and investing in private equity through leveraged buyouts. The SPAC theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize SPAC Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.